pharmaphorum

Gilead, Arcus say TIGIT combo encouraging in GI cancer

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...

TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced ...

DelveInsight Business Research, LLP: TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer ...